<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476994</url>
  </required_header>
  <id_info>
    <org_study_id>6344-001</org_study_id>
    <nct_id>NCT02476994</nct_id>
  </id_info>
  <brief_title>Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion</brief_title>
  <official_title>A Randomized, Double-Blind, Controlled, Clinical Trial to Evaluate the Risk of Developing Essential Fatty Acid Deficiency in Pediatric Patients, Including Neonates, Receiving Either Clinolipid (Lipid Injectable Emulsion, USP) 20% or Standard-of-Care Soybean Oil-Based Lipid Emulsion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a descriptive study designed to evaluate the propensity for hospitalized
      pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days
      to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will
      evaluate the safety and efficacy of using Clinolipid in a pediatric population.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on feedback from FDA
  </why_stopped>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Essential Fatty Acid Deficiency (EFAD)</measure>
    <time_frame>Up to 90 Days</time_frame>
    <description>Holman Index Calculation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parenteral Nutrition-Associated Cholestasis (PNAC)</measure>
    <time_frame>Up to 90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms in Fatty Acid Desaturase Genes FADS1 and FADS2</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty Acid Profile</measure>
    <time_frame>Up to 90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Up to 90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phytosterol, Cholesterol, and Squalene Levels</measure>
    <time_frame>Up to 90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Hepatic Integrity (ALP, AST, ALT, GGT, Total and Direct Bilirubin)</measure>
    <time_frame>Up to 90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescribed and Actual (Total Calories From PN and Oral) Nutritional Intake</measure>
    <time_frame>Up to 90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Up to 90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>Up to 30 Days After Subject's Last Study Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Up to 90 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Essential Fatty Acid Deficiency (EFAD)</condition>
  <arm_group>
    <arm_group_label>Clinolipid (lipid injectable emulsion, USP) 20%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralipid 20% (lipid injectable emulsion, USP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clinolipid</intervention_name>
    <arm_group_label>Clinolipid (lipid injectable emulsion, USP) 20%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
    <arm_group_label>Intralipid 20% (lipid injectable emulsion, USP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients and/or their legal representative must be able to understand the study and
             voluntarily sign the ICF

          2. Patients age &lt;18 years

          3. Patients who are able to adhere to protocol requirements

          4. Patients who are expected to require PN for at least 7 days

          5. Premature infants (&lt;36 weeks of gestation) require at least 80% PN to meet nutrition
             requirements at study entry; full term infants and children require at least 70% PN to
             meet nutrition requirements at study entry

        Exclusion Criteria:

          1. Patients who are not expected to survive hospitalization or with a severe illness with
             foreseeable intercurrent events that could jeopardize the patient's participation in
             the study

          2. Patients with a known hypersensitivity to lipid emulsion, egg or soybean proteins, or
             any of the active substances, excipients, or components of the container

          3. Patients with a diagnosis of shock, renal failure requiring dialysis, or severe
             metabolic acidosis (eg, pH &lt;7.10, serum bicarbonate level â‰¤15 mEq/L , and/or an Anion
             Gap &gt;16 mEq/L)

          4. Patients with hemodynamic instability as judged by the Investigator

          5. Patients with uncorrected metabolic disorders (eg, diabetes) or liver disease
             including cholestasis

          6. Patients with severe hyperlipidemia or severe disorders of lipid metabolism
             characterized by hypertriglyceridemia (triglyceride &gt;400 mg/dL)

          7. Patients who are unable to tolerate the necessary laboratory monitoring

          8. Patients who have a new and active infection (as assessed by the investigator) at time
             of initiation of study treatment

          9. Patients who are enrolled in another clinical trial involving an investigational agent

         10. Patients who were treated with IV lipids within 48 hours of randomization into the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter Healthcare Corporation</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advocate Children's Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at Indiana Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University, Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of SC, Neonatology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <results_first_submitted>October 31, 2017</results_first_submitted>
  <results_first_submitted_qc>October 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2017</results_first_posted>
  <disposition_first_submitted>February 2, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 2, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 3, 2017</disposition_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential Fatty Acids (EFA)</keyword>
  <keyword>Parenteral Nutrition</keyword>
  <keyword>Clinolipid/Clinoleic</keyword>
  <keyword>Parenteral Nutrition Associated Cholestasis (PNAC)</keyword>
  <keyword>Parenteral Nutrition Associated Liver Disease (PNALD)</keyword>
  <keyword>Intestinal Failure Associated Liver Disease (IFALD)</keyword>
  <keyword>Phytosterols</keyword>
  <keyword>Intralipid</keyword>
  <keyword>Infants/Preterm Infants</keyword>
  <keyword>FADS1 and FADS2</keyword>
  <keyword>Short Bowel Syndrome</keyword>
  <keyword>Cancer Nutrition</keyword>
  <keyword>Olive Oil Emulsion</keyword>
  <keyword>Soybean Oil Emulsion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
          <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
        </group>
        <group group_id="P2">
          <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
          <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Based on feedback from FDA</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
          <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
        </group>
        <group group_id="B2">
          <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
          <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Essential Fatty Acid Deficiency (EFAD)</title>
        <description>Holman Index Calculation</description>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Essential Fatty Acid Deficiency (EFAD)</title>
          <description>Holman Index Calculation</description>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parenteral Nutrition-Associated Cholestasis (PNAC)</title>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Parenteral Nutrition-Associated Cholestasis (PNAC)</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms in Fatty Acid Desaturase Genes FADS1 and FADS2</title>
        <time_frame>Baseline</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms in Fatty Acid Desaturase Genes FADS1 and FADS2</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatty Acid Profile</title>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Fatty Acid Profile</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phytosterol, Cholesterol, and Squalene Levels</title>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Phytosterol, Cholesterol, and Squalene Levels</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Hepatic Integrity (ALP, AST, ALT, GGT, Total and Direct Bilirubin)</title>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Hepatic Integrity (ALP, AST, ALT, GGT, Total and Direct Bilirubin)</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prescribed and Actual (Total Calories From PN and Oral) Nutritional Intake</title>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Prescribed and Actual (Total Calories From PN and Oral) Nutritional Intake</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events and Serious Adverse Events</title>
        <time_frame>Up to 30 Days After Subject's Last Study Treatment</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events and Serious Adverse Events</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Tests</title>
        <time_frame>Up to 90 Days</time_frame>
        <population>Due to early termination of the study, no formal analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
          </group>
          <group group_id="O2">
            <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
            <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Tests</title>
          <population>Due to early termination of the study, no formal analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clinolipid (Lipid Injectable Emulsion, USP) 20%</title>
          <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Clinolipid</description>
        </group>
        <group group_id="E2">
          <title>Intralipid 20% (Lipid Injectable Emulsion, USP)</title>
          <description>Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
Intralipid: Standard-of-Care Soybean Oil-Based Lipid Emulsion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Disclosure Group</name_or_title>
      <organization>Baxter Healthcare</organization>
      <email>joe_archer@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

